A novel de novo mutation in ATP1A3 and childhood-onset schizophrenia

Niklas Smedemark-Margulies,Catherine A. Brownstein,Sigella Vargas,Sahil K. Tembulkar,Meghan C. Towne,Jiahai Shi,Elisa Gonzalez-Cuevas,Kevin X. Liu,Kaya Bilguvar,Robin J. Kleiman,Min-Joon Han,Alcy Torres,Gerard T. Berry,Timothy W. Yu,Alan H. Beggs,Pankaj B. Agrawal,Joseph Gonzalez-Heydrich
DOI: https://doi.org/10.1101/mcs.a001008
2016-07-07
Molecular Case Studies
Abstract:We describe a child with onset of command auditory hallucinations and behavioral regression at 6 yr of age in the context of longer standing selective mutism, aggression, and mild motor delays. His genetic evaluation included chromosomal microarray analysis and whole-exome sequencing. Sequencing revealed a previously unreported heterozygous de novo mutation c.385G>A in ATP1A3 , predicted to result in a p.V129M amino acid change. This gene codes for a neuron-specific isoform of the catalytic α-subunit of the ATP-dependent transmembrane sodium–potassium pump. Heterozygous mutations in this gene have been reported as causing both sporadic and inherited forms of alternating hemiplegia of childhood and rapid-onset dystonia parkinsonism. We discuss the literature on phenotypes associated with known variants in ATP1A3 , examine past functional studies of the role of ATP1A3 in neuronal function, and describe a novel clinical presentation associated with mutation of this gene.
What problem does this paper attempt to address?